INTRODUCTION {#s1}
============

X-linked myopathy with excessive autophagy (XMEA, OMIM 310440) is a muscle disorder with a commonly childhood onset that affects only males. XMEA patients have weakness in the proximal muscles of lower extremities that progresses to other muscles until loss of ambulation occurs at around 50 years of age ([@DMM041244C10]; [@DMM041244C4]). Late-onset forms of the disease have also been described ([@DMM041244C6]). Although cardiac involvement is not a classic feature ([@DMM041244C10]; [@DMM041244C28]), it has recently been reported that vacuolation of cardiac muscle can also be a feature in more severe cases ([@DMM041244C22]). In muscle biopsies, membrane-bound sarcoplasmic vacuoles can be observed ([@DMM041244C10]). Only a few XMEA families have been identified worldwide. This myopathy was initially described in a large Finnish family, with five affected members and a clear X-linked recessive inheritance. The clinical course was mild, and the patients were affected by a slowly progressive muscle weakness mainly in the legs but did not lose their ability to walk. There was no evidence of cardiac or neural involvement and serum creatine kinase was elevated. By electron microscopy, an excessive number of autophagic vacuoles with staining properties of lysosomes was observed ([@DMM041244C29]; [@DMM041244C10]). Additional sporadic families with similar phenotypes were described afterwards by different groups ([@DMM041244C32]; [@DMM041244C20]). All patients were males with childhood-onset progressive weakness and wasting of skeletal muscle. Proximal muscles of the lower extremities were always initially and later predominantly affected and no other organ system was affected clinically. Later, [@DMM041244C35] reported the first Chinese-American family with XMEA, but the two affected male siblings had a severe congenital form of the disease.

XMEA is a disease caused by hypomorphic alleles of the vacuolar ATPase assembly factor (*VMA21*) gene ([@DMM041244C26]). The protein encoded by this gene is a chaperone that is involved in the correct assembly of the vacuolar ATPase (v-ATPase), which is the proton pump involved in lysosomal acidification. In XMEA, there is a decrease in assembled v-ATPases, leading to a slightly increased lysosomal pH, which in turn culminates in partial blockage of the degradative step of macroautophagy. As a consequence, a feedback mechanism is activated with higher levels of macroautophagic induction, leading to accumulation of vesicles with undigested content inside muscle fibers ([@DMM041244C26]). Six different single-nucleotide substitutions in the *VMA21* gene and two non-coding microdeletions were identified in 14 families with XMEA ([@DMM041244C26]). Four were intronic, and, in two of them, the IVS1-27A base branch point was involved. These mutations result in a 32-58% reduction in *VMA21* mRNA.

Macroautophagy, hereafter referred to as autophagy, is a recycling process for proteins and damaged organelles via lysosomes. It occurs through the formation of double-membraned structures called autophagosomes, which engulf the cargo and fuse with the lysosome for degradation. This pathway has been increasingly described as essential for muscle function and structure ([@DMM041244C15]; [@DMM041244C14]; [@DMM041244C36]). In previous years, autophagy has also been strongly implicated in differentiation of progenitor muscle cells (myoblasts) into myotubes, which are the cells that undergo maturation to form adult muscle fibers. Studies investigating the differentiation of immortalized mouse myoblasts (C2C12 cells) showed that autophagy is increased during myotube formation. This increase is essential to protect those cells against apoptosis-mediated cell death ([@DMM041244C18]). Later, the autophagy pathway was implicated in the mitochondrial degradation that needs to occur in myoblasts to allow posterior mitochondrial biogenesis for the appropriate metabolism of myotubes ([@DMM041244C31]). Those results were corroborated by studies with satellite cells that are muscle stem cells, in which autophagy plays an essential role in myotube formation ([@DMM041244C8]).

Here, we describe the first XMEA Brazilian family, with a small indel in the *VMA21* gene, and we investigated how autophagy is regulated in XMEA muscle progenitor cells. We found less-acidic lysosomes, an increase in autophagic flux in XMEA myotubes and increased myotube formation, with a higher fusion index. However, no variation in myogenic factors and no regeneration within the biopsy was found. Our findings address new pathomechanisms of this rare disease.

RESULTS {#s2}
=======

The clinical description and family history of the proband are compatible with XMEA {#s2a}
-----------------------------------------------------------------------------------

The 5-year-old propositus presented a characteristic dystrophic phenotype. He was born by cesarean delivery, in the eighth month of pregnancy, due to maternal hypertension. He showed normal mental development, walked at the age of 2 years, with weight and height always below normal. The boy could walk normally and on his heels and jump a little, but needed support from the hands to lift off the ground. Subsequently, he showed difficulties with running, climbing stairs and raising from the floor. He complained of pain in the calves, but no calf hypertrophy or joint contractures were observed. His creatine kinase level was 1330 U/l (normal value=195 U/l) and an electrocardiogram showed incomplete right bundle branch conduction. Family history revealed a clear X-linked recessive pattern of inheritance, with five affected males linked through asymptomatic females. The affected maternal grandfather, aged 48 years, was wheelchair bound from the age of 30, presenting also cardiac alterations and joint contractures in the upper limbs. He began to walk on tiptoes at the age of 25, and could not raise his arms by the age of 48. Additional affected members of this family include a brother, a nephew and a cousin of the grandfather ([Fig. 1](#DMM041244F1){ref-type="fig"}A). Fig. 1.**The XMEA patient has an accumulation of autophagic vacuoles in his muscle.** (A) Pedigree of the patient\'s family. (B) H&E staining showing the presence of basophilic inclusions. Magnification 200×, light microscopy. Scale bar: 50 μm. (C) Electron micrograph of a vacuole inside a muscle fiber. Scale bar: 0.5 µm. (D,E) Lc3 immunostaining in a muscle biopsy of a control (D) and XMEA patient (E), with a remarkable accumulation of Lc3-positive vacuoles in the patient muscle. Red, Lc3; blue, DAPI, Magnification 630×, confocal microscopy. Scale bars: 10 µm.

Vacuolation and Lc3-positive puncta are prominent in the muscle biopsy {#s2b}
----------------------------------------------------------------------

Histopathological analysis of muscle biopsy sections stained with Hematoxylin-Eosin (H&E) showed a notable presence of vacuoles in muscle fibers, as observed by the basophilic inclusions in [Fig. 1](#DMM041244F1){ref-type="fig"}B. It was also possible to observe variation in fiber caliber. Analysis of muscle proteins by immunofluorescence revealed the presence of dystrophin, α2-laminin, and α-, β- and γ-sarcoglycan in the sarcolemma (data not shown). Membrane α2-laminin staining was also detected inside the autophagic vacuoles. In addition, emerin detection revealed the presence of the protein in the nucleus.

Electron microscopy showed the presence of large autophagic vacuoles inside muscle fibers, with double membranes ([Fig. 1](#DMM041244F1){ref-type="fig"}C). Those vacuoles were confirmed as being autophagic by immunostaining for Lc3 (also known as MAP1LC3B) protein, which is present in the membranes of autophagosomes. In this case, accumulation of Lc3-positive vacuoles was observed in the XMEA muscle biopsy but not in the control biopsy ([Fig. 1](#DMM041244F1){ref-type="fig"}D,E).

The XMEA patient has a mutation in the *VMA21* gene and reduced expression of *VMA21* mRNA {#s2c}
------------------------------------------------------------------------------------------

Whole-exome sequencing was undertaken for the index case on an Illumina HiSeq 2000 platform, and a first screening for rare variants failed to identify any candidate mutations in this family, excluding mutations in known genes associated with his phenotype. As recent findings revealed that *VMA21* was a strong candidate gene to be causative of XMEA, a detailed evaluation of this gene was carried out, including the flanking intronic regions. We identified a hemizygous small deletion in intron 1 of the *VMA21* gene (NM_001017980.3: c.54-30_54-27delinsT), including the IVS1-27A base previously described. The presence of the mutation in the patient, his grandfather and his heterozygous mother was confirmed through Sanger sequencing ([Fig. 2](#DMM041244F2){ref-type="fig"}A). Analysis of *VMA21* mRNA expression in the patient\'s muscle biopsy showed a clear reduction in the expression of this gene in the muscle, compared to the muscle of three male controls ([Fig. 2](#DMM041244F2){ref-type="fig"}B). Fig. 2.**The diagnosis of XMEA is confirmed in the first-described Brazilian family.** (A) A microdeletion was observed in the *VMA21* gene in the patient, his mother and his maternal grandfather. (B) *VMA21* mRNA expression was reduced in the patient compared to three male controls. A.U., arbitrary units.

Progenitor muscle cells with mutation in the *VMA21* gene preserve their proliferation and differentiation capacities {#s2d}
---------------------------------------------------------------------------------------------------------------------

As the patient has the characteristic pathology of XMEA, we isolated progenitor muscle cells from his muscle biopsy. Myoblasts were successfully obtained, and a cellular model of the disease was generated by immortalization of those cells ([@DMM041244C13]). First, we confirmed that the cells are representative of the pathology by studying *VMA21* gene expression, which showed that expression is reduced in all studied time points in the patient-derived cells but not in the control cells ([Fig. S1A](Fig. S1A)). Interestingly, we observed a trend for higher *VMA21* expression with differentiation after 3 and 6[ ]( )days in control cells, which might indicate a novel crosstalk between myogenesis and v-ATPase assembly. The immortalization was proven to be successful, and the cells retained their ability to proliferate and to form myotubes ([Fig. S1B](Fig. S1B)).

XMEA myoblasts and myotubes have fewer acidic lysosomes {#s2e}
-------------------------------------------------------

The primary defect of XMEA is causative of an increased lysosomal pH. To investigate whether XMEA cells have the expected phenotype, we performed Lysosensor analysis. The Lysosensor probe has blue fluorescence in neutral environments, and in acidic organelles, such as lysosomes, it turns yellow. We then calculated the ratio between yellow and blue vesicles within the area of each myoblast or myotube, as an indication of lysosomal acidification ([Fig. 3](#DMM041244F3){ref-type="fig"}A). Ratio analysis showed that in control and patient cells there is no difference in acidification between myoblasts and myotubes ([Fig. 3](#DMM041244F3){ref-type="fig"}B). XMEA myoblasts and myotubes, however, accumulate fewer acidic vesicles than control cells ([Fig. 3](#DMM041244F3){ref-type="fig"}B), demonstrating that these cells have the expected phenotype of XMEA pathology. In addition, it suggests the initial step of defective autophagy in patient-derived myoblasts and myotubes. Moreover, another independent probe that relies on lysosomal acidification, namely Lysotracker, also showed that myoblasts from the patient have lower acidification ([Fig. S2B](Fig. S2B)). As a control, Mitotracker was used and no changes were observed regarding mitochondrial content ([Fig. S2](Fig. S2)A). Fig. 3.**XMEA cells are less acidic** **than control** **cells.** (A) The Lysosensor probe has yellow fluorescence in acidic organelles, in contrast to the blue fluorescence in more basic compartments. The ratio between those is used to estimate the number of acidic organelles within the area of myoblasts or myotubes. Red dashed lines show the delimitation of a single myoblast. Scale bars: 20 μm. (B) The ratio between acidic and less-acidic vesicles showed that myoblasts and myotubes from the XMEA patient have fewer acidic vesicles than control cells. Chloroquine treatment in control myoblasts mimicked the XMEA phenotype, but not in myotubes. We measured 95 cells for control myoblasts, 49 cells for control myoblasts treated with chloroquine, 87 cells for patient myoblasts, 29 cells for patient myoblasts treated with chloroquine, 27 cells for control myotubes, 15 cells for control myotubes treated with chloroquine, 30 cells for patient myotubes and 23 cells for patient myotubes treated with chloroquine. Two independent experiments were performed for untreated cells and one for chloroquine-treated cells. Experiments were performed in serum-free medium. Data are presented as mean±s.d. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001; ns, non-significant. Three-way ANOVA with Bonferroni post hoc for multiple comparisons. A.U., arbitrary units.

To confirm that the reduced ratio between acidic/less-acidic vesicles observed in XMEA cells is indeed due to a decrease in lysosomal acidification, we treated both control and patient-derived cells with chloroquine. Chloroquine treatment induces a block in autophagy by increasing lysosomal pH. In this scenario, control myoblasts have fewer acidic vesicles and mimic the XMEA phenotype ([Fig. 3](#DMM041244F3){ref-type="fig"}B). In myotubes, however, the effect of chloroquine treatment in control cells is not observed. Nonetheless, both treated control myotubes and untreated and treated XMEA myotubes have fewer acidic vesicles compared to control myoblasts, suggesting that there is a further reduction in acidic vesicles with the pathology during differentiation ([Fig. 3](#DMM041244F3){ref-type="fig"}B).

XMEA myotubes have increased autophagic flux {#s2f}
--------------------------------------------

To further investigate whether the expected alterations in autophagy with the disease were present in the initial steps of muscle formation, we investigated the presence of Lc3-positive vacuoles in control and patient-derived myoblasts and myotubes. No differences were observed between myoblasts and myotubes after 6 days of differentiation, and no distinctions could be observed between control and patient cells ([Fig. 4](#DMM041244F4){ref-type="fig"}). However, cells were cultured in serum-supplemented medium, thus autophagy is less active and Lc3-positive vacuole analysis might not reflect differences between control and patient-derived cells. Fig. 4.**Myotubes have increased autophagic flux compared to myoblasts, and patient myotubes have increased autophagic flux compared to control myotubes.** (A) Quantification of Lc3-positive vacuoles in control and patient myoblasts and myotubes with or without chloroquine treatment showed that myotubes accumulate more Lc3 vacuoles upon chloroquine treatment, indicating that they have increased autophagic flux. In addition, patient myotubes have more Lc3-positive vacuoles upon chloroquine treatment than control myotubes. (B) Representative images of control and patient myoblasts and myotubes immunostained for Lc3. Two independent experiments were performed, with 50 myoblasts or myotubes, with a sum of 50 nuclei evaluated per experiment. Red, Lc3; blue, DAPI. Magnification 630×, confocal microscopy. Scale bars: 10 µm. Data are presented as mean±s.d. \*\*\**P*\<0.0001; ns, non-significant. Three-way ANOVA with Bonferroni post hoc for multiple comparisons. A.U., arbitrary units.

Considering that reduced levels of Lc3 can be related to either low autophagic activity or higher autophagic flux, we treated the cells with chloroquine, a known inhibitor of lysosomal degradation ([@DMM041244C21]). Upon chloroquine treatment, there was an increase in the number of Lc3-positive vacuoles per area in myoblasts and myotubes, in control and patient-derived cells. Additionally, there was a higher Lc3-positive vacuole number per area in chloroquine-treated myotubes compared to myoblasts, demonstrating that myotubes have increased autophagic flux, which is more evident after the inhibition of lysosomal degradation ([Fig. 4](#DMM041244F4){ref-type="fig"}). Moreover, with chloroquine treatment, myotubes from patients have a higher number of Lc3-positive vacuoles per area, indicating that patient myotubes have increased autophagic flux compared to control myotubes.

We next analyzed levels of Lc3-II, the membrane-bound form of Lc3 protein, by western blotting. Although not statistically significant, a trend for increased levels of this protein was observed in myoblasts compared to myotubes, in both control and patient-derived cells ([Fig. 5](#DMM041244F5){ref-type="fig"}A,B). In agreement with the immunofluorescence analysis, after chloroquine treatment, the levels of Lc3-II showed a tendency to increase in control and patient myotubes ([Fig. 5](#DMM041244F5){ref-type="fig"}A,B). This observation highlights that myotubes have increased autophagic flux, which is more evident after blockage of lysosomal degradation. Fig. 5.**Myotubes have increased autophagic flux observed by increased Lc3-II levels after chloroquine treatment.** XMEA-derived myotubes have increased levels of Lc3-II after chloroquine treatment and decreased p62 levels, indicating an increase in autophagic flux. (A) Representative images of Lc3 western blotting in cells with or without chloroquine treatment, showing that myoblasts have increased Lc3-II levels. Chloroquine treatment further increased Lc3-II in myotubes, but not myoblasts, indicating an increase in autophagy flux with differentiation. (B) Densitometric quantification showed a tendency for higher basal Lc3-II levels in myoblasts. Three independent experiments were performed. Individual points were plotted±s.d. ns, non-significant. One-way ANOVA (*P*=0.0327) with Dunn\'s post hoc for multiple comparisons. (C) Representative images of beclin 1 western blotting showing that its levels do not change with differentiation or XMEA pathology. Three independent experiments were performed. (D) Representative images of p62 western blotting showing that there is a slight decrease in p62 content in myotubes, especially XMEA-derived ones. Three independent experiments were performed. A.U., arbitrary units.

Additional studies of autophagy induction proteins, such as beclin1 and p62 (also known as SQSTM1), were performed. Beclin 1 analysis showed no differences between control and patient-derived cells ([Fig. 5](#DMM041244F5){ref-type="fig"}C). However, p62 levels slightly decreased with myotube formation ([Fig. 5](#DMM041244F5){ref-type="fig"}D), especially in patient-derived cells, which correlates with increased autophagic flux.

Improved fusion of myoblasts in XMEA cells {#s2g}
------------------------------------------

We next investigated whether differentiation was altered in XMEA cells, because visually a clear difference in myotube formation was observed, as in [Fig. S1](Fig. S1)[B](B). First, we evaluated the capacity of myoblasts to fuse and form myosin-heavy-chain-positive myotubes. We then calculated the fusion index, which corresponds to the percentage of nuclei that are inside differentiated cells. A total of 11,066 nuclei were counted in control cells, and 13,334 in patient-derived cells, after 3 days of differentiation. Interestingly, XMEA myotubes had a ∼10% higher fusion index compared to control myotubes, and this difference was statistically significant ([Fig. 6](#DMM041244F6){ref-type="fig"}A,B). Fig. 6.**Improved fusion of myoblasts in XMEA cells.** (A) Representative images of control and patient cells immunostained for myosin heavy chain after 3 days of myotube differentiation with or without chloroquine treatment. Scale bars: 50 μm. (B) Fusion index calculated in control and patient cells, with and without chloroquine treatment. The fusion index was higher in the patient-derived cells than in the control cells, and treatment with chloroquine did not affect the percentage of nuclei in myotubes. We measured 45 fields for control differentiated myotubes, 35 fields for patient myotubes, and five fields for chloroquine-treated control and patient myotubes differentiated for 3 days. Three independent experiments were performed for untreated cells and one for chloroquine-treated cells. Magnification 200×, confocal microscopy. Green, myosin heavy chain; blue, DAPI. Data are presented as mean±s.d. \*\*\**P*\<0.001; ns, non-significant. Two-way ANOVA with Bonferroni post hoc for multiple comparisons.

Additional experiments aimed to investigate whether the increase in myoblast fusion was due to the defective lysosomal acidification. Control and patient myotubes were differentiated for 3 days and treated with chloroquine. In the chloroquine-treated myotubes, 277 nuclei were counted for control cells and 324 nuclei for XMEA cells. We did not observe any differences in myotube formation following chloroquine treatment ([Fig. 6](#DMM041244F6){ref-type="fig"}A,B).

Expression of myogenic genes and myofiber formation are not altered in XMEA cells {#s2h}
---------------------------------------------------------------------------------

We then examined the expression of genes involved in myogenesis, aiming to understand whether the higher fusion index observed in patient-derived cells could be due to alteration in their myogenic program. Our findings suggest that there are no alterations in the genes expressed in myoblasts, such as *MYOD* (also known as *MYOD1*) and *MYF5*, or in the expression of *MYOG*, a gene involved in differentiation, in myotubes ([Fig. 7](#DMM041244F7){ref-type="fig"}A-C). Fig. 7.**The expression of genes involved in myogenesis is not altered in XMEA patient-derived cells.** (A) *MYF5* expression showed a trend to decrease in myotubes in control and patient cells. (B) *MYOD* expression decreased with myotube formation in control and patient cells, although the differences were not statistically significant. (C) *MYOG* expression increased with myotube formation in control and patient cells, although the differences were not statistically significant. Three independent experiments were performed. Individual points were plotted±s.d. \**P*\<0.05; ns, non-significant. One-way ANOVA (*P*=0.0153 for *MYF5*, *P*=0.8798 for *MYOD* and *P*=0.0381for *MYOG*) with Dunn\'s post hoc for multiple comparisons. (D) Developmental myosin staining showing that the XMEA patient has no regenerating fibers, in contrast to a Duchenne Muscular Dystrophy (DMD) patient. Magnification 200×, fluorescent microscopy. Green, laminin; red, developmental myosin; blue, DAPI. Scale bars: 50 μm. A.U., arbitrary units.

Moreover, we evaluated whether the enhanced formation of myotubes in XMEA cells would result in the formation of new muscle fibers in the patient\'s muscle biopsy. After staining his muscle sections for development myosin heavy chain (dMHC), we did not observe new muscle fibers being formed in the XMEA biopsy, in comparison to a positive Duchenne muscular dystrophy (DMD) biopsy, in which regeneration and formation of new fibers is observed ([Fig. 7](#DMM041244F7){ref-type="fig"}D).

DISCUSSION {#s3}
==========

In this study, we describe the first Brazilian family with a pathology suggestive of XMEA. The proband showed clinical symptoms and histological findings compatible with this diagnosis. Alongside molecular findings by next-generation sequencing (NGS), the patient included in this study fulfilled the histological and molecular criteria for XMEA. Muscle biopsy analysis with H&E staining showed variation in fiber size alongside basophilic inclusions, which are consistent with several case reports from XMEA patients ([@DMM041244C4]; [@DMM041244C32]; [@DMM041244C10]; [@DMM041244C5]; [@DMM041244C12]; [@DMM041244C27]; [@DMM041244C33]; [@DMM041244C6]). All other histological and immunofluorescence analyses were also compatible with the disease. In the first described cases, the demonstration of the autophagic nature of the vacuoles was concluded based on increased activity of lysosomal enzymes ([@DMM041244C10]). Later, colocalization of the vacuoles with Lc3 was demonstrated in a vacuolar disease, possibly XMEA ([@DMM041244C35]). Our results confirm this finding, showing the presence of numerous Lc3-positive inclusions in the muscle biopsy of a patient with a confirmed mutation in the *VMA21* gene and reduction in *VMA21* mRNA expression, which is nowadays known to be causative of the disease. These observations highlight the autophagic nature of the vacuoles, together with the structural findings in electron microscopy analysis.

We next established a cellular model for *VMA21* gene mutation studies from the patient with a confirmed XMEA pathology. Considering that the *VMA21* gene product is involved in the correct assembly of the v-ATPase, deficiency in this protein complex could culminate in defective muscle formation. Alterations in the v-ATPases are widely reported in association with diseases; however, in most cases, specific subunits are affected and a total absence of v-ATPases has never been reported ([@DMM041244C7]). Additionally, v-ATPases have a wide range of functions beside lysosomal acidification, such as membrane trafficking and fusion ([@DMM041244C19]). Autophagy has an important role in muscle development and is the pathway altered in XMEA; therefore, we investigated it in progenitor immortalized muscle cells, i.e. myoblasts and myotubes, from the XMEA patient. We confirmed that the capacity of proliferation and differentiation *in vitro* is preserved, even with reduction of *VMA21* gene expression and lower acidification of XMEA myoblasts and myotubes. Intriguingly, we observed a trend for increased VMA21 expression in control myotubes, suggesting a novel link between myogenesis and VMA21 expression.

Our aim was also to understand how the pathophysiology of XMEA might be affecting autophagy during the process of muscle differentiation, since this pathway has a well-known role in myotube formation ([@DMM041244C31]; [@DMM041244C8]; [@DMM041244C18]). We found increased autophagic flux in myotubes through the analysis of Lc3 protein, both in control and patient-derived cells. It is important to note that myogenesis is a timely regulated process, and 6 days of differentiation might represent an advanced state of myotube formation. All previous studies regarding autophagic status in myotube formation were performed in mouse muscle cells ([@DMM041244C31]; [@DMM041244C8]; [@DMM041244C18]), and the only study in humans was performed with differentiation from tonsil-derived mesenchymal stem cells ([@DMM041244C24]). Therefore, this is the first study in human muscle cells to suggest activation of the autophagy pathway during normal muscle differentiation.

Interestingly, all observations related to the basal activation of the autophagic pathway were similar in control and patient-derived cells, which indicates that, at this point of muscle formation, the higher levels of autophagy activation expected with the disease, as described by [@DMM041244C26], were not yet detectable. However, when we treat cells with chloroquine, we observe that patient myotubes have higher autophagic flux compared to control myotubes, indicating that XMEA myotubes indeed have greater induction of the autophagic pathway. Therefore, muscle vacuolation and accumulation of vesicles of undigested content are probably starting in later stages of muscle formation. It is also important to consider that, in [@DMM041244C26], the autophagic pathway was investigated in fibroblasts and lymphoblast cells, which might have a distinct response from that of muscle cells.

In XMEA cells, an increased capacity to fuse and form myotubes was found. Considering that myogenesis is a tightly regulated process, with factors such as Myf5 and Myod being expressed in myoblasts and Myog in myotubes ([@DMM041244C1]; [@DMM041244C2]; [@DMM041244C25]), we further investigated whether alterations in their expression could explain the enhanced fusion in XMEA cells. Although we observed the expected changes in expression during differentiation, no differences were found between the control and patient-derived cells. In addition, the enhanced myotube formation was not translated into new myofibers being formed in the XMEA muscle, suggesting that this is a highly disease-dependent feature. However, it could contribute to changes in fiber caliber, resulting in the observed variation in fiber sizes in the muscle biopsy. These observations suggest that deregulation of myogenic factors and regeneration of muscle fibers might not be playing a role in the XMEA-increased myoblast fusion. In this sense, in a recent study analyzing a model of myoblasts with a decline in fusion capacity, the authors also observed no alteration in the expression of myogenic factors such as Myog, highlighting the possibility of morphological alterations without changes in the myogenic program ([@DMM041244C23]). Previous studies have also found enhanced fusion in myoblasts upon genetic modulation of factors such as insulin-like growth factor-1 (IGF-1) ([@DMM041244C9]), mitogen-activated protein kinase kinase kinase kinase 4 (Map4k4) ([@DMM041244C34]), matrix metallopeptidase 7 (MMP-7) ([@DMM041244C3]), creatine kinase b (CKB) ([@DMM041244C30]) or stabilin-2 (Stab-2) ([@DMM041244C23]), emphasizing the number of distinct cellular pathways that, when altered, may lead to enhanced myotube formation. Upon treating cells with chloroquine, we did not observe changes in myoblast fusion, indicating that lysosomal acidification is not the major player regulating this process. However, since v-ATPase is known to have acidification-independent functions, we hypothesize that the primary defect of XMEA can lead to an increase in myoblast fusion. In this regard, a v-ATPAse study in *Caenorhabditis elegans* demonstrated that it acts as a negative regulator of cell--cell fusion ([@DMM041244C11]). We therefore speculate that, in XMEA cells, the expected lower number of assembled v-ATPases might alleviate the repression of this mechanism, resulting in the higher myoblast fusion in the patient. Nevertheless, it remains to be elucidated whether this repression also occurs in all mammals and, moreover, whether this would be the primary cause of the enhanced cell fusion in XMEA muscle cells.

We also cannot rule out that the differentiation stimulus is indeed perceived by XMEA cells, and, as myoblast fusion is a tightly regulated process that requires proper autophagy, those cells fuse in an uncontrolled manner. Then, regardless of a higher differentiation rate, the patient-derived myotubes might not be as functional as normal muscle cells, compromising their physiology. It is also intriguing as to why a ubiquitous mechanism such as lysosomal acidification and autophagy would affect mainly the muscle in XMEA patients. In this regard, the results of the present study are bringing new evidence on impaired muscle myogenesis, with excessive myotube fusion, in the context of the XMEA phenotype.

MATERIALS AND METHODS {#s4}
=====================

Patient {#s4a}
-------

One family with five affected males was identified, linked through female carriers, with a typical X-linked pattern of inheritance. Further studies were performed with the proband in the Human Genome and Stem Cell Research Center (HUG-CELL) after obtaining a consent form from his parents.

Muscle biopsy and histology {#s4b}
---------------------------

A muscle biopsy from the biceps was obtained from the 5-year-old patient, for diagnostic purposes. The muscle sample acquired was divided to obtain myoblasts in cell culture or immediately frozen in liquid nitrogen after removal and stored at −70°C. Histological sections were made from this frozen biopsy using a cryostat (Microm HM 505E). Routine histological and histochemical analyses including staining for H&E, modified Gomori trichrome, succinate dehydrogenase, NADH, alkaline phosphatase, Sudan Black, periodic acid--Schiff, Cox Congo Red and ATPase at pH 9.4 and pH 4.3 were performed. The stained slides were observed by light microscopy (Zeiss).

Molecular analysis {#s4c}
------------------

DNA was isolated from blood by standard methodology. NGS was first performed using a customized NGS panel, with 95 genes involved in neuromuscular disorders, with Illumina\'s Nextera kits for library preparation and custom capture of these genes. Subsequently, whole-exome sequencing was carried out. Libraries were sequenced as 100-bp end runs (average insert size of 300 bases). Read alignment and variant calling was performed by Illumina CASAVA 1.9 pipeline software. An average of 120 gigabytes in aligned sequences was produced per sample, yielding a genome sampling depth of ∼40× and more than 95% of the UCSC hg19 reference genome sampled at 10 reads or more. NGS alignment and genotyping was also performed using Broad Institute\'s Best Practices (BWA 0.7; GATKv2.4; HaplotypeCaller); however, no further variants in the linked region were identified. As a downstream variant analysis, the resulting variant list for each sample was filtered using the 1000 Genomes variants (phase 1 release v3), the NHLBI Exome Sequencing Project (ESP6500) variants and the recently created Online Archive of Brazilian Mutations -- AbraOM (<http://www.abraom.ib.usp.br/>).

Cell culture {#s4d}
------------

Myoblasts from the XMEA patient were isolated using explants from his muscle biopsy. Control myoblasts were isolated from the quadriceps of an unaffected individual and were generously provided by Dr Vincent Mouly (Institut de Myologie, Paris, France). All cells were immortalized at the Institut de Myologie by a previously established protocol ([@DMM041244C13]). Importantly, the maintenance of the proliferative and differentiation capacities from the original cell lines was assessed and confirmed.

The immortalized cell lines were seeded at a density of 2.5×10^5^ cells per 75 cm^2^ and grown in proliferation medium, Skeletal Muscle Cell Growth Medium (PromoCell), with 20% fetal bovine serum (Gibco). When cells reached 100% confluence, they were switched to differentiation medium, which is composed of DMEM GlutaMAX™ (Invitrogen), 50 μg/ml gentamycin (Invitrogen) and 10 μg/ml insulin (Sigma-Aldrich).

Proliferating and 3- and 6-day-differentiated cells were collected after incubation with trypsin (Gibco) and centrifuged at 300 ***g*** for 10 min at 4°C. The cell pellets were washed with 1× PBS (Gibco) and centrifuged once more. The resulting pellets were frozen and stored at −70°C before proceeding to RNA and protein analysis. Cells were obtained from three independent experiments.

Immunofluorescence {#s4e}
------------------

Frozen muscle biopsy sections from the XMEA patient and controls were fixed with 100% methanol for 15 min at −20°C, permeabilized with 0.1% Triton X-100 (Sigma-Aldrich) for 5 min and blocked for 1 h in a solution of 1× PBS (Gibco), 5% goat serum (Sigma-Aldrich) and 0.3% Triton X-100 (Sigma-Aldrich). The histological sections were then incubated overnight at 4°C with primary antibody against Lc3 (3868, Cell Signaling Technology; 1:200) or dMHC (VP-M664, Vector Laboratories; 1:30) in a solution of 1× PBS (Gibco), 1% bovine serum albumin (Sigma-Aldrich) and 0.3% Triton X-100 (Sigma-Aldrich). Sections were washed three times in 1× PBS (Gibco), incubated with an anti-rabbit secondary antibody conjugated to Alexa Fluor 594 (11012, Invitrogen) for 1 h at room temperature and washed again. Sections were mounted with Vectashield^®^ Mounting Medium (Vector Laboratories) with 4′,6-diamidino-2-phenylindole (DAPI). The specificity of antibodies was assessed by using control samples and incubating samples with secondary antibody only. Images were obtained in a Zeiss LSM-800 confocal system with a Plan-Apochromat 63×/1.4 NA oil objective or a Zeiss microscope with epi-fluorescence.

Patient and control myoblasts were plated at 10^5^ cells per well in 6-well plates on glass coverslips. Cells were grown in proliferation medium until 70-80% confluence, when they were fixed and processed as above for Lc3 immunostaining. Another set of plates was allowed to reach 100% confluence, when they were switched to differentiation medium for 6 days. Afterwards, cells were also fixed and processed as described for muscle biopsy sections. The images obtained from two independent experiments were analyzed with ImageJ software to determine the intensity of Lc3-positive puncta per area.

Fusion index {#s4f}
------------

Myoblasts from the XMEA patient and control were plated at 10^5^ cells per well in 6-well plates on glass coverslips. Cells were grown in proliferation medium until they reached 100% confluence, when they were switched to differentiation medium for 3 or 6 days. Myotubes were fixed with 2% paraformaldehyde for 20 min, followed by permeabilization with 1× TBS with 0.1% Triton X-100 (Sigma-Aldrich) for 30 min and blocking in 1× TBS with 1% fetal bovine serum (Gibco) and 0.1% Triton X-100 (Sigma-Aldrich) for 30 min at room temperature. Cells were then incubated with an antibody against myosin heavy chain (MF-20, Developmental Studies Hybridoma Bank; 1:100) overnight at 4°C, followed by three washes with 1× TBS with 0.1% Triton X-100 (Sigma-Aldrich) and incubation with a secondary mouse antibody conjugated to Alexa Fluor 488 (11001, Invitrogen) and washed again. Slides were mounted with Vectashield^®^ Mounting Medium (Vector Laboratories) with DAPI. The specificity of antibodies was assessed by using undifferentiated control samples and incubating samples with secondary antibody only. Images were obtained in a Zeiss LSM-800 confocal system with an EC-Plan Neofluar 20×/0.5.

The fusion index was calculated as the number of nuclei inside myotubes/total number of nuclei, as measured from five fields at 20× magnification. Three independent experiments were quantified for patient-derived and control myotubes, at 3 and 6 days after switch to differentiation medium.

Lysosensor analysis {#s4g}
-------------------

Autophagic flux was evaluated based on the protocol described by [@DMM041244C17]. Myoblasts were kept for 1 h in serum-free medium to be in the same condition as myotubes at the time of Lysosensor analysis. Myotubes were evaluated after 3 days of differentiation. Cells were incubated with 2 µM Lysosensor Yellow/Blue fluorescent probe (Invitrogen) at 37°C for 1 h. *Z*-stack images of single cells and myotubes were acquired in a Zeiss LSM-800 confocal system with an EC-Plan Neofluar 40×/0.5. The excitation filters used to obtain the images were 425 nm (emission of 446 nm, to see the less-acid vesicles, represented in blue) and 519 nm (emission of 543 nm, to see the more-acid vesicles, represented in yellow). Fluorescence signal was quantified on the sum projection of *Z*-stacks. Cells were manually outlined and the integrated density was measured using ImageJ software (<https://imagej.nih.gov/ij/>). Three random areas around the cells were measured to subtract background noise. Then, the ratio between yellow and blue fluorescence was calculated.

Chloroquine treatment {#s4h}
---------------------

Control and patient myoblasts and myotubes were incubated with 60 µM chloroquine (Abcam) diluted in proliferation or differentiation medium for 24 h. Cells were collected as described above and the cell pellet was processed for protein extraction. Patient and control myoblasts and myotubes were also cultivated in glass coverslips, and incubated with 60 µM chloroquine (Abcam) diluted in proliferation or differentiation medium for 24 h. Live cells were used for Lysosensor experiments. In addition, cells were fixed and processed as described above for Lc3 immunofluorescence. Finally, myotubes were fixed and processed for fusion index calculation.

Flow cytometry analysis {#s4i}
-----------------------

Control and patient myoblasts were seeded at a density of 2.5×10^5^ cells per 75 cm^2^ and grown in proliferation medium until they reached 70-80% confluence. Cells were detached using trypsin (Gibco) and 10^6^ cells from each line were stained by incubating cells at 37°C with 250 nM MitoTracker Red FM (MM22425, Invitrogen) or 50 nM LysoTracker Red DND-99 (LL7528, Invitrogen), according to the manufacturer\'s instructions. Cells were then analyzed by a flow cytometer Aria (BD Biosciences) in three independent experiments. For mean fluorescence intensity determination, FlowJo software (<https://www.flowjo.com/>) was used.

RNA analysis {#s4j}
------------

Fragments of frozen muscle from the patient and controls and the previously obtained cell pellets were used for total RNA extraction using the TRIzol protocol (Invitrogen). The obtained RNA was solubilized in RNase-free water (Ambion™) and quantified in a Nanodrop spectrophotometer (Thermo Fisher Scientific). cDNA synthesis was performed using 1 µg total RNA according to the M-MLV protocol (Invitrogen). Specific sets of primers were used for analyses of autophagic and myogenic genes and *TBP* was used as an endogenous control ([Table 1](#DMM041244TB1){ref-type="table"}). Real-time PCR was performed in triplicate for *VMA21* gene expression analysis and duplicates for the remaining genes using the FastStart Universal SYBR Green Master Rox (Roche) on a thermocycler 7500 Fast (Applied Biosystems). The fold change was obtained by the 2^−ΔΔCT^ method, with *TBP* and the control muscles or myoblasts as normalizers for autophagic genes, and the respective undifferentiated samples for myogenic genes.Table 1.**Primer sequences**

Protein analysis {#s4k}
----------------

Cell pellets were homogenized in RIPA buffer (Sigma-Aldrich) supplemented with 1% protease and phosphatase inhibitors (Sigma-Aldrich). Samples were kept on ice for 30 min and afterwards centrifuged at 16,000 ***g*** for 20 min at 4°C, followed by protein quantification by the bicinchoninic acid assay (Pierce, Thermo Fisher Scientific). Homogenized samples were separated by SDS-PAGE, and transferred to nitrocellulose membranes (Amersham Pharmacia). The membranes were then probed using the following antibodies: anti-Lc3 (3868, Cell Signaling Technology; 1:1000), anti-p62 (5114, Cell Signaling Technology; 1:200), anti-beclin1 (sc-11427, Santa Cruz Biotechnology; 1:500) and anti-α-tubulin (T5168, Sigma-Aldrich; 1:1000). The specificity of antibodies was assessed using positive controls. The membranes were then incubated with the appropriate secondary horseradish peroxidase-conjugated anti-rabbit or anti-mouse antibodies (Thermo Fisher Scientific) and revealed using a Novex™ ECL Chemiluminescent Substrate Reagent kit (Invitrogen). For the reaction with the endogenous control, membranes were stripped with a stripping buffer (Thermo Fisher Scientific) and re-probed for α-tubulin analysis. Bands were quantified by densitometry using ImageJ.

Statistical analysis {#s4l}
--------------------

Data were expressed as mean±s.d. Differences between each control and the patient and between myoblasts and myotubes were assessed by one-way ANOVA with Dunn\'s post hoc for multiple comparisons in cases of quantitative PCR or western blotting experiments that were performed three independent times. Two-way ANOVA with Bonferroni post hoc for multiple comparisons was used when analyzing data obtained for fusion index experiments, comparing myoblasts and myotubes, untreated or treated with chloroquine. For Lysosensor and Lc3 vacuole detection experiments comparing myoblasts and myotubes, treatments and controls and the patient, three-way ANOVA with Bonferroni post hoc for multiple comparisons was used. All analyses were performed using GraphPad Prism. *P*\<0.05 was considered significant.

This article is part of a special collection 'A Guide to Using Neuromuscular Disease Models for Basic and Preclinical Studies', which was launched in a dedicated issue guest edited by Annemieke Aartsma-Rus, Maaike van Putten and James Dowling. See related articles in this collection at <http://dmm.biologists.org/collection/neuromuscular>.
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